Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07407660 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

Name: Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax — clinical trial record (NCT07407660)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorPeking University People's Hospital

Started2026-02-01

View on ClinicalTrials.gov ↗

Peking University People's Hospital

220 trials monitored

See 6 trials at risk

Leukemia

2,553 trials monitored

See 134 trials at risk

Acute Myeloid Leukemia (AML)

1,196 trials monitored

See 63 trials at risk

This study aims to compare the efficacy and safety of a shortened treatment course based on the bone marrow blast count on Day 14 versus standard treatment in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.

Trial Details

NCT Number	NCT07407660
Lead Sponsor	Peking University People's Hospital Collaborators: Shanghai Qianzhanruiji Enterprise Consulting Co., Ltd.
Conditions	Acute Myeloid Leukemia
Enrollment	250 participants
Start Date	2026-02-01
Primary Completion	2028-02-01 (estimated)
Study Completion	2030-02-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-12